UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
UCBJY is expected to report earnings to fall 85.79% to 11 cents per share on February 28
Q4'23
Est.
$0.12
Q2'23
Missed
by $0.08
The last earnings report on July 27 showed earnings per share of 83 cents, missing the estimate of 91 cents. With 23.91K shares outstanding, the current market capitalization sits at 33.38B.